Clinical Trial

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Study acronym: ADAM
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to standard of care (SOC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-03-03; most recent amendment 2024-06-18.
Status change: Recruiting → Active, Not Recruiting 2024-06-18
Status change: Active, Not Recruiting → Recruiting 2021-01-04
Status change: Not Yet Recruiting → Active, Not Recruiting 2020-08-24
Trial Details
NCT Number NCT04295447
Lead Sponsor Universität Münster
Collaborators: Janssen Pharmaceutica N.V., Belgium
Conditions Prostatic Neoplasms
Enrollment 190 participants
Start Date 2020-12-10
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-20